Early-access Avacopan in Real-world ANCA-associated Vasculitis
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Jan 22, 2025
Trial Information
Current as of June 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the use of a medication called avacopan for patients with ANCA-associated vasculitis, a condition that affects the blood vessels and can harm different organs in the body. The researchers want to understand how avacopan is being used in real-world settings across Europe, particularly focusing on how patients respond to this treatment and the characteristics of those who receive it. By gathering this information, the study aims to improve the way avacopan is used and potentially fill in gaps in our understanding of this medication.
To be part of this trial, participants need to have been diagnosed with either Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) and should be starting treatment with avacopan. The study is open to adults aged 16 and older. Participants will be asked to provide consent for their medical data to be used in the research, and they can expect to share their experiences and outcomes while being treated with avacopan. This trial is currently recruiting participants and hopes to gather valuable insights that could help improve treatment for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Established diagnosis of GPA or MPA
- • Treatment (initiation) with avacopan
- • Informed consent for use of medical data
- Exclusion Criteria:
- • If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment
- • If a subject is below 16 years old
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leiden, Zuid Holland, Netherlands
Patients applied
Trial Officials
Y.K. Onno Teng
Principal Investigator
Leiden University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported